UK MHRA Approves Pfizer-BioNTech XBB 1.5 mRNA Vaccine Via European Commission Decision! 

The United Kingdom&rsquo;s drug and vaccine regulatory, the Medicines and&nbsp;Healthcare products Regulatory Agency (MHRA) yesterday, approved the Pfizer-BioNTech mRNA COVID-19 vaccine targeting Omicron XBB 1.5 subvariant. Even though no clinical trials have been completed, nor formal peer-reviewed research has been published&mdash;and the national emergency is now terminated---the UK regulatory reports its &ldquo;standards of safety, quality and effectiveness&rdquo; have been approved. In the USA and the UK, XBB strains of the Omicron SARS-CoV-2 virus become ever less predominant in dynamic, evolving situations.
The UK regulatory went ahead and approved the use of the BNT162b2 monovalent version for XBB.1.5 for all individuals aged 6 months of age and up.